Based on key technology, the 1064nm laser, the CardioVascLas® System was tested for minimally invasive treatment of cardiovascular disorders including cardiac tachyarrhythmia, systemic and pulmonary hypertension, hypertrophic obstructive (HOCM) and parasitic (Chagas) cardiomyopathies and for side selective interatrial septal puncture Experimental and clinical tests. By evaluating over 1000 in-vitro and in-vivo experimental and clinical laser applications open-irrigated, non-contact laser applications under normothermic conditions showed unique and superior ablation effects and safety aspects. Research and study design, results achieved, unique aspects such as myocardial tissue selective laser wavelengths, high-density lasermapping are described. Significant outcome and further scope to continue research are indicated. It is concluded that laser ablation with the CardioVascLas-System® is a promising alternative for the treatment of cardiovascular disorders.
Keywords: Catheter ablation, 1064nm laser, cardiac tachyarrhythmias, retrocardiac ganglion plexi, perivascular renal and pulmonary innervation, HOCM, Chagas, systemic and pulmonary resistant hypertension, side selective transseptal laser puncture.
Citation: Weber, H. et al., (2025). Minimally Invasive Laser Catheter Treatment of Cardiovascular Disorders. I J cardio & card diso; 6(4):1-14. DOI : https://doi.org/10.47485/2998-4513.1050